Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.

Journal of controlled release : official journal of the Controlled Release Society - 1 Aug 2024

Kim Ha Rin, Park Seong Jin, Cho Young Seok, Moyo Mudhibadhi Knowledge, Choi Jeong Uk, Lee Na Kyeong, Chung Seung Woo, Kweon Seho, Park Jooho, Kim Byoungmo, Ko Yoon Gun, Yeo Joo Hye, Lee Jinu, Kim Sang Yoon, Byun Youngro

Abstract excerpt

KRAS-mutant cancers, due to their protein targeting complexity, present significant therapeutic hurdles. The identification of the macropinocytic phenotype in these cancers has emerged as a promising alternative therapeutic target. Our study introduces MPD1, an macropinocytosis-targeting peptide-drug conjugates (PDC), which is developed to treat KRAS mutant cancers. This PDC is specifically designed to trigger a...

Topics

Join the communities discussing this publication.

Antineoplastic Agents
DNA-Activated Protein Kinase
Mice, Nude
Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Protein Kinase Inhibitors

Proto-Oncogene Proteins p21(ras)

Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 38880331
DOI: 10.1016/j.jconrel.2024.06.028

Genes

KRAS
PDC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.PMID 38880331Read ↗

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.Semantic proximity Read ↗

Albumin metabolism targeted peptide-drug conjugate strategy for targeting pan-KRAS mutant cancer.Semantic proximity Read ↗

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Semantic proximity Read ↗

Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.Semantic proximity Read ↗

An in situ immunogenicity-amplifying payload delivery system for immunotherapy of Kirsten rat sarcoma viral oncogene homolog-mutant cancer.Semantic proximity Read ↗

Precision medicine by designer interference peptides: applications in oncology and molecular therapeuticsSemantic proximity Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

Discovery of cell active macrocyclic peptides with on-target inhibition of KRAS signalingSemantic proximity Read ↗

Alternative approaches to target Myc for cancer treatmentSemantic proximity Read ↗

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.Semantic proximity Read ↗

Modulating Protein-Protein Interactions of the Mitotic Polo-like Kinases to Target Mutant KRAS.Semantic proximity Read ↗

The Dual Role of Macropinocytosis in Cancers: Promoting Growth and Inducing Methuosis to Participate in Anticancer Therapies as TargetsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.